AGC Inc. has synthesized compounds acting as prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) antagonists reported to be useful for the treatment of cancer.
2A Biosciences Inc. has described phenethylamines acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.
Merck Sharp & Dohme LLC has prepared and tested triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of Alzheimer’s disease and neurodegeneration.
Obesity and diabetes are known risk factors for sarcopenia. Insulin resistance that occurs during type 2 diabetes promotes impaired synthesis of muscle protein and muscle breakdown. Juvena Therapeutics Inc. has presented data at ENDO 2025 conference for JUV-161, a novel secreted protein that induces insulin sensitization, regarding its impact on blood glucose and muscle in mice with type 2 diabetes (db/db mice).
Multiple sclerosis (MS) is a degenerative and inflammatory condition of the central nervous system (CNS) that impacts more than 2.5 million individuals globally. Interleukin-33 (IL-33) is an immunoregulatory cytokine that has shown a mild inhibitory effect on experimental autoimmune encephalomyelitis (EAE), which serves as a mouse model for MS. However, its clinical application is limited by unfavorable pharmacokinetics and associated toxicity.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, with few successful treatment options. HCC development is associated with established risk factors, including metabolic dysregulation, repeated insults by hepatotoxins or infection by hepatotropic viruses.
A recent study published in the journal International Immunopharmacology presents compelling preclinical evidence that NIMA-associated kinase 7 (NEK7), a key regulator of inflammation, may play a pivotal role in the pathology of depression.
Acromegaly is a rare, chronic endocrine disorder characterized by excessive secretion of growth hormone (GH), most commonly resulting from a benign pituitary adenoma.
Researchers from the University of Copenhagen and the Psychiatric Center Copenhagen have uncovered the cellular and synaptic effects of the drug VU-0364572, a selective modulator of the M1 muscarinic acetylcholine receptor.
RSS
